The patent for Eliquis, a medication developed by Bristol-Myers Squibb and Pfizer, is set to expire in 2026 [1]. However, the availability of generic versions of Eliquis may not be immediate. According to a report, the first generic versions of Eliquis have been approved by the FDA, but their launch might be delayed until 2026 or even later due to ongoing litigation between the manufacturers and potential generic competitors [2]. Therefore, it is uncertain when exactly generic versions of Eliquis will be available on the market. A news article also mentions that a generic version of Eliquis won't be available for several years [3].

In conclusion, the patent for Eliquis is scheduled to expire in 2026, but the availability of generic versions may be delayed due to ongoing litigation. It is unclear when exactly generic versions of Eliquis will be accessible to consumers.

Sources:
[1] Drug Patent Watch. Eliquis Trademark Details. Retrieved from: https://www.drugpatentwatch.com/p/tradename/ELIQUIS
[2] FiercePharma. First generics to Bristol-Myers and Pfizer's Eliquis are here, but might not launch until 2026 or later. Retrieved from: https://www.fiercepharma.com/pharma/first-generics-to-bristol-myers-and-pfizer-s-eliquis-are-here-but-might-not-launch-until
[3] Fox Carolina. FDA approved generic version of Eliquis, but it won't be available for several years. Retrieved from: https://www.foxcarolina.com/2023/01/14/fda-approved-generic-version-eliquis-it-wont-be-available-several-years/